APLS - Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting | Benzinga
- Late-breaking presentation shows SYFOVRE® (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension study
WALTHAM, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that six abstracts, five of which are oral presentations, will be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 17 - 20 in Stockholm, Sweden. These data reinforce the robust efficacy and well-documented safety profile of SYFOVRE® (pegcetacoplan injection) for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
"We look forward to sharing data that further demonstrate why SYFOVRE is the most chosen GA treatment by retina specialists, highlighting its ability to slow disease progression with increasing effects over time," said Caroline Baumal, M.D., chief medical officer, Apellis. "We are thrilled to present results showing that SYFOVRE demonstrated a visual function benefit in a prespecified microperimetry endpoint at 36 months in GALE."
Presentations include:
- Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: Anchored Matching-Adjusted Indirect Comparisons of Three Phase 3 Trials Over 24 Months – Paul Hahn, MD, PhD, FASRS - Dry AMD Symposium 1 - Wednesday, July 17, 9:31-9:35 a.m. CEST
- Identification of Disease Activity and Therapeutic Response in Geographic Atrophy by Human Experts and OCT-Based AI Analysis in Pegcetacoplan Therapy – Ursula M Schmidt-Erfurth, MD - Expert Panel: Artificial Intelligence - Wednesday, July 17, 11:00-11:20 a.m. CEST
- Predictive Role of Outer Retinal Tubulation in Lesion Growth for Subfoveal and Nonsubfoveal Geographic Atrophy - Srinivas Sai A Kondapalli, MD - Imaging Symposium 1 – Thursday, July 18, 8:34-8:38 a.m. CEST
- Update on Pegcetacoplan for Geographic Atrophy: Clinical Studies and Real-World Experience - David A Eichenbaum, MD, FASRS - Expert Panel: Pegcetacoplan – Thursday, July 18, 3:25-3:45 p.m. CEST
- Visual Function Benefit of Pegcetacoplan on a Prespecified Microperimetry Endpoint after 36 Months of Continuous Treatment from GALE - Sunir J Garg, MD, FACS, FASRS - Expert Panel: Pegcetacoplan - 3:25-3:45 p.m. CEST
- Beneficial Effects in Macular Function With Continuous Pegcetacoplan Treatment: OAKS, DERBY, and GALE Open-Label Extension - Mathew W MacCumber, MD, PhD, FASRS - POD 1: AMD
About GALE Long-Term Extension Study
GALE (n=792) is a Phase 3, multicenter, open label, extension study to evaluate the long-term safety and efficacy of SYFOVRE® (pegcetacoplan injection) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The objectives of the study are to evaluate the long-term incidence and severity of ocular and systemic treatment emergent adverse events as well as change in the total area of GA lesions as measured by fundus autofluorescence. More than 80 percent of participants who completed the OAKS and DERBY studies entered the GALE study.
GALE also includes ...